EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Late-phase impact of CMV/EBV reactivation on survival after hematopoietic stem-cell transplantation: a 5-year single-center cohort study

Shanshan Li, Mei Jia, Liyan Cui

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1782595 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Shanshan Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Cytomegalovirus, Herpesvirus 4, Human, Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether simultaneous cytomegalovirus (CMV) and Epstein–Barr virus (EBV) reactivation confers additional late mortality beyond isolated CMV remains controversial.

Methods

We retrospectively analyzed 202 consecutive first-ever hematopoietic stem cell transplantations performed between 2018 and 2019, using twice-weekly PCR surveillance and uniform preemptive therapy. Cox models were used to estimate hazard ratios (HRs) for overall survival (OS) and leukemia-free survival (LFS) at the 1-, 3-, and 5-year landmarks.

Results

Although 1-year outcomes were similar, divergence emerged thereafter: 5-year OS was 19.4% with coreactivation, 36.6% with isolated CMV, and 25.1% with no reactivation ( p = 0.041); corresponding LFS was 19.4%, 36.6%, and 25.2% ( p = 0.060). Multivariate analysis identified sustained CMV replication as the dominant late risk factor (OS HR 5.295, 95% CI 1.5888–17.6464; p = 0.0067), whereas coreactivation lost significance because EBV clearance shortened the overall viral window. Interestingly, viral enteritis was identified as an independent adverse predictor of 1-year LFS (HR 6.2453, 95% CI 1.3245–7.2376; p = 0.0010).

Conclusions

Late mortality is driven by persistent CMV-driven endothelial injury rather than transient EBV coreactivation. Extending PCR surveillance from day 100 to year 2 and targeting chronic low-level CMV should be prioritized to improve long-term transplantation success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusHerpesvirus 4, HumanHematopoietic Stem Cell TransplantationCytomegalovirus InfectionsEpstein-Barr Virus InfectionsVirus ActivationLatent InfectionCoinfectionHumansMaleFemaleAdultRetrospective StudiesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaChina

Stichwörter der Autor:innen

CMVEBVHSCTlong-term survivalreactivation

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.
  • Core Unit of National Clinical Research Center for Laboratory Medicine, Peking University Third Hospital, Beijing, China.
  • Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.

Zitieren

APA

Li, S., Jia, M., & Cui, L. (2026). Late-phase impact of CMV/EBV reactivation on survival after hematopoietic stem-cell transplantation: a 5-year single-center cohort study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1782595

Vancouver

Li S, Jia M, Cui L. Late-phase impact of CMV/EBV reactivation on survival after hematopoietic stem-cell transplantation: a 5-year single-center cohort study. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1782595

BibTeX
@article{Li2026,
  author = {Li, Shanshan and Jia, Mei and Cui, Liyan},
  title = {Late-phase impact of CMV/EBV reactivation on survival after hematopoietic stem-cell transplantation: a 5-year single-center cohort study},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1782595}
}
Kostenlos starten →